Lurasidone (Latuda®) – Generic Availability in 2023
| Region | Generic Approval Date | Commercial Availability |
|--------|-----------------------|--------------------------|
| United States (FDA) | September 2023 (generic “Lurasidone Hydrochloride” submitted by Lupin Pharmaceuticals) | Commercially available on Sept 6, 2023 – the first U.S. generic hit the shelves in major pharmacies and through most insurers. |
| Canada (Health‑Canada) | October 2023 | Generic lurasidone was approved in Oct 2023 and entered the market shortly thereafter. |
| Australia (TGA) | November 2023 | Approved in Nov 2023; available in pharmacies across the country. |
| Europe (EMA) | Late 2023 / early 2024 (varies by country) | Most EU members granted approval in late‑2023 or early‑2024; availability depends on national regulatory bodies. |
Key Points
1. First U.S. Generic
- Manufacturer: Lupin Pharmaceuticals, India.
- Approval: FDA’s “Generic Drug Application” (GDA) was cleared in September 2023.
- Launch: The generic entered the U.S. market the same month, providing a cost‑effective alternative to the branded Latuda® (Merck).
2. Insurance & Formularies
- Most U.S. insurance plans now list the generic as the preferred or first‑line choice for schizophrenia and bipolar disorder maintenance therapy.
- Copay tiers are typically lower compared to the brand name.
3. Availability in Other Markets
- Canada & Australia: Generic approvals followed closely after the U.S., reflecting similar regulatory pathways and the high demand for antipsychotic cost savings.
- Europe: Generic lurasidone approvals are country‑specific; several EU countries (e.g., France, Germany, Italy) approved the generic in late 2023, while others followed in 2024.
4. Clinical Equivalence
- The generic lurasidone is bioequivalent to the branded product (absorption, distribution, metabolism, and excretion profiles match the reference).
- No clinically meaningful differences in efficacy or safety have been reported in post‑market surveillance.
5. Dosage Forms
- Both brand and generic offer 10 mg, 20 mg, 40 mg, 80 mg, and 120 mg oral tablets.
- Generic packaging mimics the brand (same tablet shape/color) to aid patient transition.
Practical Takeaway
- Cost Savings: Patients and payers who switched to the generic saw average cost reductions of 35–50 % per month.
- Access: In 2023, the generic became widely available in the U.S., Canada, and Australia, with the EU catching up later that year.
- Switching: When moving from branded to generic, ensure the pharmacist verifies that the patient is receiving the correct dosage and monitors for any perceived differences (though none are expected).
If you have specific questions about your coverage, formulary status, or how to switch safely, let me know—I can help you find the right resources or contact information for your insurer or pharmacy.